MXCT furnishes Q3 2025 prelim results and reaffirms 2025 revenue outlook

Rhea-AI Filing Summary

MaxCyte, Inc. furnished a current report announcing preliminary unaudited financial results for the quarter ended September 30, 2025 and reiterated its full‑year 2025 revenue guidance. The details are provided in a press release attached as Exhibit 99.1. The company stated that the information is furnished and not deemed filed under Section 18 of the Exchange Act, and is not incorporated by reference except as expressly set forth by specific reference.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

0001287098false00012870982025-11-052025-11-05

​

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

​

​

FORM 8-K

​

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

​

Date of Report (Date of earliest event reported): November 5, 2025

​

​

MaxCyte, Inc.

(Exact name of registrant as specified in its charter)

​

​	​	​	​	​
Delaware		001-40674		52-2210438
(State or other jurisdiction of incorporation)	​	(Commission File Number)	​	(IRS Employer Identification No.)

​

9713 Key West Avenue, Suite 400

Rockville, Maryland 20850

(Address of principal executive offices, including zip code)

​

(301) 944-1700

(Registrant’s telephone number, including area code)

​

N/A

(Former name or former address, if changed since last report)

​

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

​

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

​

Securities registered pursuant to Section 12(b) of the Act:

​

​	​	​	​	​
Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.01 par value	​	MXCT	​	The Nasdaq Stock Market LLC

​

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

​

Emerging growth company    ☒

​

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial account standards provided pursuant to Section 13(a) of the Exchange Act. ☐

​

​

​

​

Item 2.02. Results of Operations and Financial Condition.

​

On November 5, 2025, MaxCyte, Inc. (the “Company”) issued a press release announcing preliminary unaudited financial results for the quarter ended September 30, 2025 and reiterating its full year 2025 revenue guidance. A copy of this press release is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K.

​

The information in this Current Report on Form 8-K, including Exhibit 99.1 hereto, is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section. The information contained herein and in the accompanying exhibit is not incorporated by reference in any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof and irrespective of any general incorporation language in any filings, except as expressly set forth by specific reference in such a filing.

​

Item 9.01. Financial Statements and Exhibits.

​

(d) Exhibits

​

Exhibit Number		Exhibit Description
​	​	​
99.1	​	Press Release, dated November 5, 2025
104	​	Cover Page Interactive Data (embedded within the Inline XBRL document)

​

​

​

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

​

​	​	​
​	MaxCyte, Inc.
​	​
Dated: November 5, 2025	By:	/s/ Douglas Swirsky
​	​	Douglas Swirsky
​	​	Chief Financial Officer

​

​

​

FAQ

What did MaxCyte (MXCT) announce in its 8-K?

The company furnished preliminary unaudited results for the quarter ended September 30, 2025 and reiterated full‑year 2025 revenue guidance.

Where can I find the detailed results for MXCT?

Details are in the press release attached as Exhibit 99.1.

Is the information in this 8-K considered filed or furnished?

It is furnished and not deemed filed under Section 18 of the Exchange Act.

Which period does the update cover for MXCT?

The quarter ended September 30, 2025.

What is MaxCyte’s trading symbol and exchange?

The common stock trades on The Nasdaq Stock Market LLC under the symbol MXCT.

Who signed the report for MaxCyte?

It was signed by Douglas Swirsky, Chief Financial Officer.

What exhibits were included with this 8-K?

Exhibit 99.1 (press release) and Exhibit 104 (Cover Page Inline XBRL).